To synthesize, integrate, and comment on recent research developments to our understanding of the molecular basis of ependymoma (EPN), and to place this in context with current treatment and research efforts.
Our recent understanding of the histologically defined molecular entity EPN has rapidly advanced through genomic, transcriptomic, and epigenomic profiling studies.
These advancements lay the groundwork for development of future EPN biomarkers, models, and therapeutics. Our review discusses these discoveries and their impact on our clinical understanding of this disease. Lastly, we offer insight into clinical and research areas requiring further validation, and open questions remaining in the field.
aDepartment of Pediatrics, Baylor College of Medicine
bDepartment of Pediatric Hematolgy and Oncology, Texas Children's Cancer and Hematology Centers, Houston, Texas, USA
cDivision of Neurosurgery, Program in Developmental and Stem Cell Biology, Arthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, Ontario, Canada
Correspondence to Dr Michael D. Taylor, The Hospital for Sick Children, 555 University Ave. Rm 1504, Toronto, ON, Canada M5G 1X8. Tel: +1 416 813 7564; e-mail: email@example.com